Heron Therapeutics, Inc.HRTXNASDAQ
Loading
Year-over-year operating cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | -790.01% |
| Q3 2025 | 112.25% |
| Q2 2025 | -22.53% |
| Q1 2025 | 24.70% |
| Q4 2024 | -449.45% |
| Q3 2024 | 173.22% |
| Q2 2024 | 51.62% |
| Q1 2024 | -487.62% |
| Q4 2023 | 126.75% |
| Q3 2023 | 66.21% |
| Q2 2023 | -9.10% |
| Q1 2023 | 33.66% |
| Q4 2022 | -1.26% |
| Q3 2022 | -30.64% |
| Q2 2022 | 35.43% |
| Q1 2022 | 2.91% |
| Q4 2021 | 14.87% |
| Q3 2021 | 15.60% |
| Q2 2021 | -50.20% |
| Q1 2021 | 20.20% |
| Q4 2020 | -24.97% |
| Q3 2020 | 26.58% |
| Q2 2020 | -73.91% |
| Q1 2020 | -22.09% |
| Q4 2019 | -5.91% |
| Q3 2019 | -10.23% |
| Q2 2019 | 52.86% |
| Q1 2019 | -46.40% |
| Q4 2018 | 6.66% |
| Q3 2018 | 40.92% |
| Q2 2018 | 1.59% |
| Q1 2018 | -30.89% |
| Q4 2017 | -16.30% |
| Q3 2017 | -26.57% |
| Q2 2017 | 36.68% |
| Q1 2017 | -31.31% |
| Q4 2016 | -6.66% |
| Q3 2016 | -33.22% |
| Q2 2016 | 16.20% |
| Q1 2016 | -39.75% |